Lantern Pharma Announces Spinout: Open‑Medicine AI Created

What Happened
Lantern Pharma, Inc. announced on August 3, 2026 (via an 8‑K/Regulation FD disclosure) that it has established a new separate company, Open‑Medicine AI, to commercialize and expand Lantern’s multi‑agent AI co‑scientist platform for drug development. A press release describing the action was furnished as Exhibit 99.1 to the Form 8‑K.

Key Details

• Announcement date: August 3, 2026 (Regulation FD disclosure on Form 8‑K, Item 7.01).
• New entity: Open‑Medicine AI formed as a separate company to commercialize and expand Lantern’s multi‑agent AI co‑scientist platform.
• Filing: The press release was furnished as Exhibit 99.1 to the Form 8‑K; Exhibit listings also appear under Item 9.01.

Why It Matters
This move formalizes Lantern’s separation of its AI drug‑development technology into a standalone company, clarifying that the AI platform is being positioned for commercialization and growth. For investors, it’s a material strategic development to watch — future SEC filings, press releases or disclosures may provide details on ownership, financing, partnerships, or licensing that could affect Lantern’s business focus and potential value from the AI platform.